Hormonal

Tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with a high signal for gastrointestinal adverse events (specifically gastroesophageal reflux disease and dyspepsia) and injection site reactions in real-world post-marketing data, alongside unexpected signals for increased appetite and food craving.

If you are taking tirzepatide, expect gastrointestinal issues like reflux or dyspepsia and injection site reactions (pain, bruising) to be common. Interestingly, while the drug is designed to suppress appetite, some users report increased appetite or food cravings in real-world reports. Monitor your blood glucose if you have diabetes, and report severe abdominal pain (pancreatitis risk) or severe injection site bleeding to your doctor immediately.